AnaptysBio Beats Q3 2026 Estimates as Revenue Falls 60% to $30.3M
Revenue of $30.3M vs. $25.6M expected and EPS of $0.11 vs. -$1.84; revenue down 60% from a year earlier.
AnaptysBio (ANAB) beat estimates for the third quarter of 2026 on both revenue and EPS. Revenue was $30.3 million, down 60% from a year earlier, above the $25.6 million estimate, and EPS was $0.11, down 79% from a year earlier, above the -$1.84 estimate.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| EPS | -$1.84 | $0.11 | Beat by 106% |
| Revenue | $25.6M | $30.3M | Beat by 18% |
| Change | YoY | QoQ |
|---|---|---|
| EPS | ▼ 79% | ▼ 98% |
| Revenue | ▼ 60% | ▲ 10% |
By our calculation, revenue was $4.7 million above the estimate and EPS was $1.95 above it. The QoQ column compares with the previous quarter's revenue of $27.5 million and EPS of $5.11. The YoY column compares with $76.3 million and $0.52 in the same quarter a year earlier.
GAAP results
- Net income. The company reported net income of $3.9 million on a GAAP basis, compared with net income of $15.1 million a year earlier.
Track record
- EPS record. EPS beat the estimate in 6 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 7 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $76.3 million, $108.2 million, $25.6 million, $27.5 million and $30.3 million.
What to watch
- Next-quarter estimates. Consensus calls for EPS of $5.11 and revenue of $27.5 million next quarter, based on 3 analysts.
- Revenue growth. Whether revenue stabilizes after this quarter's 60% decline from a year earlier to $30.3 million.
- Estimate record. Whether AnaptysBio extends a record of beating EPS estimates in 6 of its last 8 reports.
- Related coverage. See our reports on Arrowhead Pharmaceuticals, Dlocal, Erasca and Nektar Therapeutics.
Sources: Results are from AnaptysBio's Nov. 12, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from AnaptysBio's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Arrowhead Pharmaceuticals Misses Fiscal Q4 2026 Estimates as Revenue Falls 85% to $37.8M
EarningsDlocal Q3 2026 EPS Tops Estimates at $0.23, but Revenue Misses at $398.1M
EarningsErasca Falls Short of Q3 2026 Estimates
EarningsNektar Therapeutics Q3 2026 EPS Tops Estimates at -$1.63, but Revenue Misses at $9.4M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
